1 / 42

Washington Update Florida Society of Clinical Oncology (FLASCO)

Washington Update Florida Society of Clinical Oncology (FLASCO). Clifford Hudis , MD President, ASCO Chief, Breast Cancer MedService , MSKCC Professor of Medicine, WCMC. Disclosures. I do not intend to discuss an off-label use of a product during this activity

nishan
Télécharger la présentation

Washington Update Florida Society of Clinical Oncology (FLASCO)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Washington UpdateFlorida Society of Clinical Oncology (FLASCO) Clifford Hudis, MD President, ASCO Chief, Breast Cancer MedService, MSKCC Professor of Medicine, WCMC

  2. Disclosures • I do not intend to discuss an off-label use of a product during this activity • I have not had any relevant financial relations during the past 12 months to disclose (but am on the ASCO BOD).

  3. Good News Mortality Five-Year Survival Source: National Cancer Institute Source: National Cancer Institute

  4. What’s Ahead New Cancer Cases Source: National Cancer Institute

  5. Challenges • Economic pressures • Political turbulence • General disruption across medicine • Sequestration • ICD-10 • PQRS, Meaningful Use • Health Reform • ACOs, shifts in practice environment • Performance based payment • Wave of newly insured • Uncertainty

  6. Repeal SGR Formula SGR Repeal and Medicare Provider Payment Modernization Act of 2014

  7. SGR Rollercoaster Dec 2009: Congress freezes rates for two months. Mar 2010: CMS holds claims. Apr 2010: CMS advises physicians to hold claims Jun 2010: Congress delays cut until November 30 Nov 2010: Congress freezes rates for one month Dec 2010: President signs bill for one-year delay to 25 percent cut. Feb 2011: Congress delays cut with 10-month patch Feb 2012: Congress delays until Jan of 2013 Jan 2013: Congress delays for one year Dec 2013: Congress delays until April 1, 2014 Mar 2014: Bipartisan agreement then failed. Patch # 17 passed

  8. The Big Picture: State Of Cancer Care in America • 530 practices • 8,011 physicians http://www.asco.org/practice-research/cancer-care-america

  9. Top Concerns

  10. Other Concerns • Health Insurance Exchanges • Network adequacy • 90-day grace period • Coverage for cancer care • General dysfunction/confusion

  11. Community Practices At Risk • Likelihood of Practice Change • Private Community Practice, By Practice Size • 25% reduction in private practices since 2012 census • 2/3 of smaller practices anticipate sale, merger or closing in next year—double that reported overall • Small medium practices see >1/3 new patients

  12. Smaller Community Practices • Backbone of U.S. cancer care delivery system • Serve more than one third of all new patients, especially in the South • Nearly two-thirds (63%) of these practices likely to merge, sell or close in the next year

  13. Geographic Challenges:Oncologists Per 100,000 by state

  14. Supply-Demand Perspective 300 New Patients/per year x 1,487 Oncologist Shortage 446,100 New Patients Face Challenges

  15. Taking Action: Health Reform • Essential Health Benefits for cancer patients • State-by-state analysis • Communication with White House on 90-day grace period • Monitoring network adequacy

  16. Taking Action: Payment Reform • Information series on ASCO in Action • CPC workgroup developing/testing alternative models • Joint statement with COA, USON, ION • Oncology medical home • Episode based payments • Close communication with Congressional committees • Representation on CMS technical panel • Working with other medical organizations and the AMA

  17. What You Can Do Help us… Help you!

  18. Research Funding: FY 14 NCI: $4.9 billion

  19. Stagnant Research Budget

  20. Our Message • 2014 increases not a budget victory for medical research • Does not go far enough • Adjusting for inflation, NIH budget below 2013 levels

  21. Outlook for 2015 • Probable request: • $32 bil for NIH • $5.2 bil for NCI • Keeps pace with medical inflation • Not likely to happen

  22. Why Consider Value?Society Focused On Consider Costs of Cancer Care? • Cost affects access and outcomes • Out of pocket costs matter to patients, and affect treatment decisions • Cost matters to payers • Cost matters to society

  23. US Health Spending at 17.7% of GDP is ~50% Greater than Others (and Still Rising) • Projected US Health Spending 2020 → 20% GDP • Kehhan SP, Cuckler GI, Sisko AM, Madison AJ, Smith SD, Lizonito JM, Poisal JA and olfe CJ. National Health Expenditure Projections: Modest Annual Growth Until Coverage Expands And Economic Growth Accelerates. Health Affairs. 2012 Jul;31(7):1600-12.

  24. Higher Spending Does Not Increase Life Expectancy Health Care Expenditures and Life Expectancy (2005) Fuchs VR, Milstein A. N Engl J Med 2011;364:1985-1987.

  25. Patients are Bearing More of the Costs Projected family health insurance premium costs and average household income Household Income Year Annals of Family Medicine: 2012: 10: 156-162

  26. Cost of Cancer Care is Rising • → $125 billion in 2010 • → $175 billion in 2020

  27. Cancer Care Costs Rising Faster than Overall Healthcare Cancer Drugs Cumulative % Increase Cancer Medical Healthcare US GDP Source: Blue Cross Blue Shield Association

  28. Hospitals and Providers a large fraction

  29. Eight of Top Ten Most Expensive Drugs Covered by Medicare are Cancer Drugs Top Ten Medicare Drugs 2012 Millions Ranibizumab $ 1,220 • Rituximab cancer treatment $ 876 • Infliximab injection $ 704 • Injection pegfilgrastim , 6mg $ 642 • Bevacizumab injection $ 624 • Aflibercept 1 mg $ 384 • Denosumab injection $ 347 • Oxaliplatin $ 309 • Pemetrexed injection $ 292 • Bortezomib injection $ 278 • . • Source: Moran Company Analysis of Medicare Physician/Supplier Procedure Summary File, 2012. Includes carrier claims only (physician office and DME). Outpatient Prospective Payment System (OPPS) claims are excluded.

  30. Challenge:Cost Seldom Considered by Stakeholders

  31. Value = What is “Value”? “the regard that something is held to deserve; the importance, worth, or usefulness of something.” Benefit(s) ------------------------------------------------ (Financial Cost + Non-financial Cost)

  32. Defining & Increasing Value: Unique Challenges for Oncology • Sense of urgency as many cancer patients have a poor prognosis and are facing imminent death • Pressures to use newest technologies/treatments • Treatments are expensive, making appropriate cancer care a hardship or unaffordable • Treatments can be highly toxic/life-threatening (secondary expenses) • Providers, patients & families often reluctant to switch to best supportive care, even at the obvious end of life Source: 2009 IOM Report: Assessing and Improving the Value in Cancer Care

  33. Each Stakeholder Has a Role • Providers: trying innovative ways to responsibly control costs while improving quality, through mechanisms such as clinical pathways and adherence to evidence-based medicine • Payers: looking to assure highest and best use of limited resources through the development of innovative benefit designs and pay for performance mechanisms • Patients: mobilizing to promote access through initiatives such as uniform patient assistance programs, patient navigation, and education of individuals and families about the cost of care • Manufacturers: finding ways to innovate in the most cost-effective and efficient way possible

  34. ASCO’s Efforts to Lower Costs, Increase Value • Promoting Adherence to Evidence-Based Medicine: ASCO Guidelines • Participating in & Promoting “Choosing Wisely” • Commitment to Quality Improvement: QOPI • Working with Payers: Integration of Quality Measures into Reimbursement Decision-Making • Cultivating a Learning Healthcare System: CancerLinQ • Establishing Clinically Meaningful Outcomes in Cancer Research • Payment Reform • The Value in Cancer Care Task Force

  35. Taking Action: Cost and Value • Value Task Force developing framework • Sharing with CPC and State Affiliate Council • Presentation at annual meeting • Drug Cost Summit • Industry • Providers • Payers • Patients

  36. The Way Forward • Cost control + no quality monitoring/measurement = inappropriate care • Payer-driven quality efforts must include improved outcomes • Promising initiatives • Solution: Quality measurement, meaningful and feasible to healthcare providers

  37. Growth in QOPI Since 2006

  38. Whatever the path… • Fee for service unlikely to remain dominant model • Prospective payment models are the trend • Shifts reward from volume to efficiency • Risk will move from over- to under-utilization • Because of this, require strong quality measurement programs • Need a national program created by—and meaningful to—oncology professionals • Working to qualify QOPI as means of reporting to Medicare • PQRS historically not meaningful in oncology • QOPI developed by oncology professionals • Aim is to avoid each payer creating their own • eQOPI anticipated by fall 2014 • CancerLinQ in 2015

More Related